Scott Coward - EXACT Sciences Sr. VP and General Counsel

EXAS Stock  USD 53.66  0.59  1.11%   

SVP

Mr. D. Scott Coward is Senior Vice President, Chief Administrative Officer, General Counsel, Secretary of the Company. He has served as our Senior Vice President, General Counsel and Secretary since January 2015 and as our Chief Administrative Officer since July 2018. He joined us from the global law firm KL Gates LLP, where he practiced corporate and securities law and served as managing partner of the Raleigh, NC office. Prior to his tenure at KL Gates, Mr. Coward served as General Counsel of Blue Rhino Corporationrationration, a leading supplier of consumer propanerelated products. Prior to Blue Rhino, Mr. Coward served as an Associate General Counsel at GE Medical Systems in Milwaukee, WI, and prior to that, as a partner at the Raleigh, NC law firm Smith Anderson Blount Dorsett Mitchell Jernigan LLP since 2018.
Age 59
Tenure 6 years
Address 5505 Endeavor Lane, Madison, WI, United States, 53719
Phone608 284 5700
Webhttps://www.exactsciences.com
Coward earned a bachelor degree in business administration from the University of North Carolina—Chapel Hill and a JD from Columbia Law School.

EXACT Sciences Management Efficiency

The company has return on total asset (ROA) of (0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0676) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Intangibles To Total Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.38 in 2024, whereas Fixed Asset Turnover is likely to drop 1.58 in 2024.
EXACT Sciences currently holds 2.55 B in liabilities with Debt to Equity (D/E) ratio of 0.77, which is about average as compared to similar companies. EXACT Sciences has a current ratio of 2.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about EXACT Sciences' use of debt, we should always consider it together with its cash and equity.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people. EXACT Sciences (EXAS) is traded on NASDAQ Exchange in USA. It is located in 5505 Endeavor Lane, Madison, WI, United States, 53719 and employs 6,500 people. EXACT Sciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

EXACT Sciences Leadership Team

Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeffrey CFA, Chief Officer
Kevin Conroy, Chairman of The Board, CEO and Pres
Ana Hooker, Chief Officer
Aaron Bloomer, Executive Finance
James Herriott, General VP
Vic Parker, Head Sales
Sarah Condella, Executive Resources
Sri Kalluri, Chief Officer
Tim Caprez, Chief VP
Brian Baranick, Executive Oncology
Nassar Nizami, Chief Officer
Everett Cunningham, Chief Officer
Scott Coward, Sr. VP and General Counsel
Jake MBA, Executive Screening
Graham Lidgard, Chief Science Officer and Sr. VP
Kevin JD, Chairman CEO
Jorge Garces, Chief Officer
Megan Jones, Associate Relations

EXACT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for EXACT Stock Analysis

When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.